Gemcitabine  Chemical Structure

Gemcitabine Chemical Structure
Molecular Weight: 263.2

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

Gemcitabine is available in the following compound libraries:

Product Information

  • Compare DNA/RNA Synthesis Inhibitors
    Compare DNA/RNA Synthesis Products
  • Research Area

Product Description

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTBwMECwOFU5KG6PM2LLS3NCVkeHUh?=
ES4MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnWN2ozUUN3ME2wMlAxODZ3MzDuUS=>M1;0SHNCVkeHUh?=
ACHNNILac4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrGTWM2OD1yLkCwNFg5PyCwTR?=NXrYXYNXW0GQR1XS
KYSE-510NFjIXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHZTWM2OD1yLkCwNFk4PSCwTR?=MWTTRW5ITVJ?
EW-7Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDyTWM2OD1yLkCwNlU5KG6PNWLlO5ZKW0GQR1XS
BFTC-905MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDNTWM2OD1yLkCwOVE2KG6PMUjTRW5ITVJ?
KE-37NWXXSmoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvBPIZKSzVyPUCuNFA2PjFibl2=NGDzNFdUSU6JRWK=
SBC-5MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfMTWM2OD1yLkCwOVchdk1?MX;TRW5ITVJ?
NKM-1NYrucVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1Hp[mlEPTB;MD6wNFcxQSCwTR?=MnvRV2FPT0WU
RH-1MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYqzV3VVUUN3ME2wMlAxPzF6IH7NNIG1RZlUSU6JRWK=
ALL-POMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7P[GVKSzVyPUCuNFA5OyCwTR?=NXL2Vo1HW0GQR1XS
QIMR-WILNYfMPZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTBwMEC4PVQhdk1?NUnW[W1LW0GQR1XS
A375MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlGxTWM2OD1yLkCwPVk2KG6PMXjTRW5ITVJ?
SIG-M5MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMEGwOEBvVQ>?MVzTRW5ITVJ?
KGNM2HLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;hWWlEPTB;MD6wNVA5KG6PM3jyNnNCVkeHUh?=
EW-13MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{j3RmlEPTB;MD6wNVEzKG6PNF3a[lRUSU6JRWK=
NCI-SNU-1M3j2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljBTWM2OD1yLkCxOkBvVQ>?M4HsdXNCVkeHUh?=
PSN1NILX[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MomzTWM2OD1yLkCxOlUhdk1?NUnXVZM2W0GQR1XS
HUTU-80MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\MbJBKSzVyPUCuNFE3PiCwTR?=NUTJe|h4W0GQR1XS
EW-16M1\PUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TSeGlEPTB;MD6wNlMhdk1?NX30PGw5W0GQR1XS
786-0Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TlWGlEPTB;MD6wNlMhdk1?MljDV2FPT0WU
ES1MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\BTWM2OD1yLkCyOlghdk1?MkS1V2FPT0WU
RKONV3xbXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\ZZ|BwUUN3ME2wMlAzPzlibl2=NX;5fVdRW0GQR1XS
ESS-1M1fMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XJXWlEPTB;MD6wNlg3KG6PNWroS5ZvW0GQR1XS
SK-UT-1NXTHOpRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mme1TWM2OD1yLkCyPVchdk1?MWTTRW5ITVJ?
LB2241-RCCMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTBwMEOxPEBvVQ>?NInDZpBUSU6JRWK=
CHL-1NXy4dZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHMd3ljUUN3ME2wMlA{OjRibl2=NX72UlU2W0GQR1XS
SW1783NXPkNI5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\teWlEPTB;MD6wN|M3KG6PNUS3TYkyW0GQR1XS
MEL-JUSOM3OyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLDTWM2OD1yLkCzPVEhdk1?M3rTN3NCVkeHUh?=
HT-29NWC2dWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTBwMESxN{BvVQ>?NHPXVGRUSU6JRWK=
SNG-MMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rCVGlEPTB;MD6wOFI2KG6PM1zoWXNCVkeHUh?=
TE-15M4\Nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmG2TWM2OD1yLkC0OlQhdk1?NIOwXYVUSU6JRWK=
HOSNWfO[nFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTYUWlKSzVyPUCuNFQ5KG6PMn;PV2FPT0WU
BB65-RCCM3PadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPF[GJKSzVyPUCuNFUyOiCwTR?=NFWxS|hUSU6JRWK=
HCE-4MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTBwMEWyPEBvVQ>?NFnIe|dUSU6JRWK=
MHH-ES-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjs[GdvUUN3ME2wMlA2OzFibl2=MY\TRW5ITVJ?
RPMI-7951Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnUTWM2OD1yLkC1OFEhdk1?M3PyZ3NCVkeHUh?=
IST-SL2MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mon0TWM2OD1yLkC1PFQhdk1?NXuwUHVsW0GQR1XS
CMKMkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17YdmlEPTB;MD6wOVg3KG6PMkDGV2FPT0WU
GR-STM3X3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDocJpKSzVyPUCuNFU6PSCwTR?=MYLTRW5ITVJ?
NALM-6M4L2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmX3TWM2OD1yLkC2NlIhdk1?NGHjcG1USU6JRWK=
RPMI-6666NV7GUHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTBwME[1NkBvVQ>?NVfwUJBOW0GQR1XS
LC-2-adMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTBwME[1N{BvVQ>?NXvWe|NkW0GQR1XS
ARH-77NWHnZmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\XVINbUUN3ME2wMlA4OTFibl2=MkjUV2FPT0WU
IST-MEL1Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMEeyOkBvVQ>?NILISo1USU6JRWK=
SW1710MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjCTWM2OD1yLkC3OVEhdk1?MV3TRW5ITVJ?
DELM1HtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{ntdmlEPTB;MD6wPFg4KG6PNGHlbZJUSU6JRWK=
AGSMmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXPTWM2OD1yLkC5NFIhdk1?MlrXV2FPT0WU
NCI-H2122M1zRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHwUZpKSzVyPUCuNFk1PiCwTR?=NX\OS4ZnW0GQR1XS
HSC-4MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPBRWt6UUN3ME2wMlExOiCwTR?=NYGyUYU4W0GQR1XS
AM-38NHX4UYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwMUKxJI5OMofQV2FPT0WU
769-PMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvjTWM2OD1yLkGyN{BvVQ>?M2HuXnNCVkeHUh?=
RT-112NUPJRpBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmK5TWM2OD1yLkGyO{BvVQ>?MoXVV2FPT0WU
MCF7MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHmfWZKSzVyPUCuNVM3KG6PMUfTRW5ITVJ?
IGROV-1NYjXbYlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPGTWM2OD1yLkG0OUBvVQ>?MoC0V2FPT0WU
OCI-AML2M3PGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLmOXFOUUN3ME2wMlE1PyCwTR?=MXnTRW5ITVJ?
NCI-H1299NF7CbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLMRWpKSzVyPUCuNVU4KG6PMX7TRW5ITVJ?
A431NU\yNnNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTkeXdMUUN3ME2wMlE5OyCwTR?=MVvTRW5ITVJ?
SW982M4\FVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;5TGlEPTB;MD6yNVMhdk1?NULGdHNsW0GQR1XS
BB30-HNCNHPR[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\GTWM2OD1yLkKzNUBvVQ>?M3jaVnNCVkeHUh?=
ACNMmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTBwMkS0JI5OMlvKV2FPT0WU
647-VNEHK[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfEVIVvUUN3ME2wMlI1QCCwTR?=M1;SenNCVkeHUh?=
SK-PN-DWMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrzO2ZQUUN3ME2wMlI3PiCwTR?=NX:1S3VtW0GQR1XS
LCLC-97TM1M4DCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfIdppKSzVyPUCuNlY4KG6PMXTTRW5ITVJ?
LB1047-RCCMmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Hme2lEPTB;MD6yOlkhdk1?Mlq1V2FPT0WU
A2780M1XOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fjXGlEPTB;MD6yO{BvVQ>?M4G3THNCVkeHUh?=
C-33-ANULyd|ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTBwMkezJI5OMknCV2FPT0WU
NCI-H2228MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrzTWM2OD1yLkOxOEBvVQ>?NXnwOm1mW0GQR1XS
TE-5M1;BbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jjfWlEPTB;MD6zNVYhdk1?NYXuc|c{W0GQR1XS
HC-1NUfxS3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTBwM{K3JI5OMoHiV2FPT0WU
SK-MES-1NVH0OGd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{f1Z2lEPTB;MD6zNlghdk1?NV:4dJdEW0GQR1XS
NCI-H1355NGDMS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTBwM{ixJI5OMVnTRW5ITVJ?
YKG-1MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljSTWM2OD1yLkSxPUBvVQ>?Mn\0V2FPT0WU
RS4-11NWnQZ3YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3CT4NKSzVyPUCuOFM{KG6PMWTTRW5ITVJ?
DaoyMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTITWM2OD1yLkS1OkBvVQ>?MVnTRW5ITVJ?
A3-KAWMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonhTWM2OD1yLkW1NUBvVQ>?NV3jWWRZW0GQR1XS
SK-MEL-30MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDlWWhKSzVyPUCuOVU1KG6PNGG5SWhUSU6JRWK=
U031NUT5O5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHJVIJKSzVyPUCuOVY2KG6PMmTPV2FPT0WU
SK-LMS-1MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTBwNUe4JI5ONX\NeoJ7W0GQR1XS
ES6MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHabpFKSzVyPUCuOVg3KG6PMUDTRW5ITVJ?
EoL-1-cellMo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;VU2lEPTB;MD62NVYhdk1?NHzsT2lUSU6JRWK=
NCI-H2009NFraNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwNkG5JI5OMV3TRW5ITVJ?
A4-FukNFWzWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTBwNkK2JI5ONFLt[XhUSU6JRWK=
KYSE-270NED6dFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDTdFh1UUN3ME2wMlY{PCCwTR?=MV;TRW5ITVJ?
SK-LU-1NUCzR2J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPCN49KSzVyPUCuOlU2KG6PNEi3S2ZUSU6JRWK=
SW872M1L1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTBwN{[1JI5OM3vIfnNCVkeHUh?=
ES8NX3scINjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXaTWM2OD1yLke4JI5OM2DiOXNCVkeHUh?=
G-402NFLqO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLIeolLUUN3ME2wMlc5PCCwTR?=NEj0TJRUSU6JRWK=
ATN-1NF3E[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DtVWlEPTB;MD64NFchdk1?NUOwOlJsW0GQR1XS
DoTc2-4510NGTHNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTBwOUCxJI5OMV3TRW5ITVJ?
MES-SAMk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3v3VWlEPTB;MD65NFUhdk1?NVq2RW5qW0GQR1XS
SF268MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7KTWM2OD1yLkmyO{BvVQ>?NGL1fm1USU6JRWK=
SF539MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPHRnFKUUN3ME2xMlAzKG6PMXjTRW5ITVJ?
NB69NEHpTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPHdYFKSzVyPUGuNFUhdk1?NWPEW4F5W0GQR1XS
8505CNVzSVZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTFwME[gcm0>NUjXZ|h3W0GQR1XS
CAL-12TMoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4e0OWlEPTB;MT6wPEBvVQ>?MoTMV2FPT0WU
BHYM2K5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPmXXUxUUN3ME2xMlE1KG6PMmfKV2FPT0WU
LB647-SCLCNVHNe3JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPobFZKSzVyPUGuNVghdk1?Mo\aV2FPT0WU
CAL-62MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Lh[mlEPTB;MT6yNkBvVQ>?NHuzcHVUSU6JRWK=
MEG-01NITmVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\nXJVKSzVyPUGuNlchdk1?NX;CXYRFW0GQR1XS
MG-63M3vWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnTXnZVUUN3ME2xMlM{KG6PMmXqV2FPT0WU
SW620MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfwPWNKSzVyPUGuN|Uhdk1?NFzlZ49USU6JRWK=
A388MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LNZWlEPTB;MT6zOkBvVQ>?NVTTT5NrW0GQR1XS
BCPAPMojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LicGlEPTB;MT60OUBvVQ>?NXHwVlRjW0GQR1XS
P30-OHKM3f5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmC5TWM2OD1zLkS2JI5OMYfTRW5ITVJ?
Ca9-22MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXNfVBWUUN3ME2xMlU1KG6PNHLhSINUSU6JRWK=
VMRC-RCZNGf5eZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHWNZFKSzVyPUGuOVQhdk1?NEno[HBUSU6JRWK=
LOXIMVIMkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;qTWM2OD1zLk[gcm0>M2H6W3NCVkeHUh?=
L-540MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTFwNjDuUS=>M2DVNnNCVkeHUh?=
NTERA-S-cl-D1NWfLVo1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fyN2lEPTB;MT62OEBvVQ>?Ml6yV2FPT0WU
MFH-inoMl;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjYU3VKSzVyPUGuOlYhdk1?NFL1Z|FUSU6JRWK=
Calu-6MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHizNpNKSzVyPUGuO|Mhdk1?NF\SPXRUSU6JRWK=
HELMkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfBb2V4UUN3ME2xMlc6KG6PMWTTRW5ITVJ?
CAL-33MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEf2OplKSzVyPUGuPFkhdk1?M{TKV3NCVkeHUh?=
HSC-3MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\ycJRwUUN3ME2xMlkyKG6PMVzTRW5ITVJ?
KU812MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkm5TWM2OD1zLkmxJI5ONGH3OWZUSU6JRWK=
EB2M2\ENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rwWmlEPTB;Mj6wNUBvVQ>?MmHFV2FPT0WU
SRM1jEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYmxWGdPUUN3ME2yMlEzKG6PM{GxXXNCVkeHUh?=
NCI-H2087M{jzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M32ybGlEPTB;Mj6xOEBvVQ>?M3XkVHNCVkeHUh?=
H4MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTJwMUigcm0>M{Xoc3NCVkeHUh?=
EW-1MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvOTWM2OD1{LkKyJI5OMnm3V2FPT0WU
MC-IXCNV;kUWJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPEfGpKSzVyPUKuNlYhdk1?NEfzc4hUSU6JRWK=
NCI-H727NYLtbXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV[4d5lwUUN3ME2yMlUyKG6PNH\y[JBUSU6JRWK=
MRK-nu-1M3TZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjOb3BKSzVyPUKuOVchdk1?M1PS[XNCVkeHUh?=
COLO-668MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml:wTWM2OD1{Lk[2JI5OMmXtV2FPT0WU
CGTH-W-1Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7QeVhzUUN3ME2yMlczKG6PM4fpUnNCVkeHUh?=
CHP-212NV\EcWRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTJwN{Wgcm0>NFvnO5lUSU6JRWK=
GI-1M3vMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLNT4I2UUN3ME2yMlc3KG6PMkWyV2FPT0WU
HCC1806MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzWd21KSzVyPUKuPVEhdk1?NGfN[HhUSU6JRWK=
HLEM1Lmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHW[ZI6UUN3ME2zJI5OM3GxdHNCVkeHUh?=
HSC-2MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\EUFlKSzVyPUOuNFMhdk1?NHH6dGNUSU6JRWK=
DMS-273MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTNwMEegcm0>MkD5V2FPT0WU
DU-4475NGnwZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrMNFIxUUN3ME2zMlE1KG6PMW\TRW5ITVJ?
LXF-289MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzoTWM2OD1|LkOxJI5OM4LPS3NCVkeHUh?=
PANC-03-27NXztNpByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TjcGlEPTB;Mz61NUBvVQ>?NITJPWdUSU6JRWK=
GAMGMofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjnVmJKSzVyPUOuO|Qhdk1?MVLTRW5ITVJ?
NCI-H522NW\3TWh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnpTWM2OD12LkO0JI5OMnvyV2FPT0WU
SW626NEfEUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTRwNE[gcm0>NEHIUWJUSU6JRWK=
HT-144MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\GTWM2OD12LkmyJI5OMWHTRW5ITVJ?
MEL-HONILsTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELwd3NKSzVyPUWuNVYhdk1?M{HpenNCVkeHUh?=
BE-13M4Dvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXnUGVXUUN3ME21MlIyKG6PMlPmV2FPT0WU
VA-ES-BJMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTVwMk[gcm0>M4\mcXNCVkeHUh?=
NCI-H441M4DRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\tbGlEPTB;NT62JI5OMV3TRW5ITVJ?
KP-4MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\TTJdKSzVyPUWuOlEhdk1?NV7ycGIzW0GQR1XS
LoVoNWrje2I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnESXdKSzVyPUWuO|Ehdk1?NIqxWXhUSU6JRWK=
HT-1080NXvaUJViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoexTWM2OD13LkizJI5OMkX5V2FPT0WU
GB-1NYC4RY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1r5bWlEPTB;NT64OEBvVQ>?M3rNVnNCVkeHUh?=
IA-LMM3vGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13LWWlEPTB;NT65NUBvVQ>?MlnhV2FPT0WU
8-MG-BANFK4VIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXJcY9KSzVyPUWuPVMhdk1?M3\6PHNCVkeHUh?=
SK-HEP-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGL3bWdKSzVyPU[uNVQhdk1?MVPTRW5ITVJ?
697MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1X2NmlEPTB;Nj6yOUBvVQ>?MkKzV2FPT0WU
KYSE-450MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rUTmlEPTB;Nj6zNkBvVQ>?MnPQV2FPT0WU
HCC2998NVXS[Fl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkX1TWM2OD14LkO0JI5ONEPYWHZUSU6JRWK=
HD-MY-ZNYq4eY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\X[ppNUUN3ME22MlY5KG6PNUHHclZxW0GQR1XS
OS-RC-2NIrFSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlr3TWM2OD14Lk[4JI5ONHrMU2VUSU6JRWK=
SF126Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3wblcxUUN3ME23MlA2KG6PNVHHNIRDW0GQR1XS
Ca-SkiM4XtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljuTWM2OD15LkC5JI5ONHHxfWdUSU6JRWK=
NCI-H358NVTSbY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHRTWM2OD15LkG2JI5OMoW4V2FPT0WU
J82MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml[0TWM2OD15LkSxJI5OMoXMV2FPT0WU
NCI-H2342M1fUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTpTWM2OD15Lk[zJI5ONVPHSJhQW0GQR1XS
OVCAR-8NYSzWIxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTdwOTDuUS=>MXjTRW5ITVJ?
TE-8NHLDVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVH2[|lQUUN3ME24JI5OMUHTRW5ITVJ?
ETK-1MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrnOXg2UUN3ME24MlA5KG6PM4ezcnNCVkeHUh?=
HAL-01M33CZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M32x[mlEPTB;OD6yJI5OMVvTRW5ITVJ?
KYSE-150MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;MeJZKSzVyPUiuOFchdk1?NG\Me3VUSU6JRWK=
NCI-H810MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRThwNU[gcm0>M3XTcHNCVkeHUh?=
ONS-76MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfhbnRTUUN3ME24MlY5KG6PMlS4V2FPT0WU
NMC-G1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rnWGlEPTB;OD63OkBvVQ>?MXvTRW5ITVJ?
C3AMkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRThwOESgcm0>NUn3PZJGW0GQR1XS
PA-1NGnW[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInDOJlKSzVyPUiuPVkhdk1?NIizSmZUSU6JRWK=
SH-4Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;lTWM2OD17LkCyJI5ONHfnWW1USU6JRWK=
EFO-27NXvqfm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjaTWM2OD17LkC1JI5OM4S1ZXNCVkeHUh?=
CAPAN-1NYLKTZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nLUmlEPTB;OT6yN{BvVQ>?M3f0THNCVkeHUh?=
DU-145MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHz1V21KSzVyPUmuNlkhdk1?MmG4V2FPT0WU
A101DNH60e|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTlwM{egcm0>MYXTRW5ITVJ?
ST486M3X5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPne|ZKSzVyPUmuOFEhdk1?MVjTRW5ITVJ?
NCI-H1437NWS2WmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4D0U2lEPTB;OT60NkBvVQ>?NGjmWYpUSU6JRWK=
HGC-27M2\2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTlwNjDuUS=>M1zuVXNCVkeHUh?=
8305CMlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmK3TWM2OD17Lk[0JI5ONYfQcHFKW0GQR1XS
OCUB-MNVL4e295T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLnSnFKSzVyPUGwMlA{KG6PMXTTRW5ITVJ?
COLO-679M4r5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jzNmlEPTB;MUCuNFchdk1?NV3DPFgyW0GQR1XS
Detroit562NGrER2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYe0Wod2UUN3ME2xNE41OiCwTR?=MmD2V2FPT0WU
A204NYfIWI1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NESydo1KSzVyPUGxMlE3KG6PNFv1blVUSU6JRWK=
NCI-H1734NGe0dYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLQS2RxUUN3ME2xNU4zQSCwTR?=NETyflBUSU6JRWK=
MC-CARM{fVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXPOHh[UUN3ME2xNU42QCCwTR?=MVzTRW5ITVJ?
NCI-H2170MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTFzLkm3JI5ONVjZPJBHW0GQR1XS
NCI-SNU-5MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTTPG9KSzVyPUGyMlE{KG6PMV7TRW5ITVJ?
HCE-TM{DkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTvPHAyUUN3ME2xNk41OiCwTR?=MlXjV2FPT0WU
KYSE-180NVj3WlhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTF{LkixJI5OMYjTRW5ITVJ?
C8166M1;tOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTF|LkC4JI5OMk\NV2FPT0WU
NCI-H460M2LxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HvcmlEPTB;MUOuOVQhdk1?NHXRUVVUSU6JRWK=
SNU-449MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2f3[2lEPTB;MUOuO|chdk1?MYDTRW5ITVJ?
MDA-MB-468MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjqOo5KSzVyPUG0MlEzKG6PNWHXeHNkW0GQR1XS
COR-L23MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\wTWM2OD1zND6xN{BvVQ>?MmHSV2FPT0WU
CTV-1NWPMSlFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHBcJdKSzVyPUG0MlE1KG6PM2XKTnNCVkeHUh?=
BL-41M4LCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDRTWM2OD1zND6zO{BvVQ>?MYjTRW5ITVJ?
IGR-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzHUmFtUUN3ME2xOE41OiCwTR?=NYnuZ5hUW0GQR1XS
TK10NYTY[GdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTF2LkS5JI5OMlLiV2FPT0WU
REHNVrZe3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jvW2lEPTB;MUSuOVEhdk1?NYjsOYJFW0GQR1XS
LU-139M{DOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHn6XVdKSzVyPUG0MlU6KG6PNHT0PYhUSU6JRWK=
KP-N-YSNULpcYllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moq2TWM2OD1zND65O{BvVQ>?MkCxV2FPT0WU
PANC-10-05NWfxXJhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7tR5BuUUN3ME2xOU4{QCCwTR?=M3jpUnNCVkeHUh?=
HL-60M13Kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrjbm9KSzVyPUG1MlY6KG6PM1e4fXNCVkeHUh?=
T84M4DQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofUTWM2OD1zNT65OkBvVQ>?NILreFhUSU6JRWK=
RPMI-8226MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTF4LkCyJI5ONULoTYszW0GQR1XS
UM-UC-3MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTF4LkG2JI5OMmjqV2FPT0WU
TE-10NF7RUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnCTWM2OD1zNj6yNUBvVQ>?NEjaXXFUSU6JRWK=
CAL-148MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnncoRJUUN3ME2xO{4zOyCwTR?=NXPTelRlW0GQR1XS
BV-173NVXEUpM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrGSJRKSzVyPUG3MlI4KG6PNVTFbFl2W0GQR1XS
Calu-3MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\kNGlEPTB;MUeuNlkhdk1?MlizV2FPT0WU
RPMI-2650MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLaPWpoUUN3ME2xO{42QSCwTR?=NFqxTHRUSU6JRWK=
MKN45MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHPTWM2OD1zNz63N{BvVQ>?M13vNnNCVkeHUh?=
NUGC-3M{nVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoKyTWM2OD1zOD6zOEBvVQ>?M1PnbnNCVkeHUh?=
NCI-H520MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFj2[nBKSzVyPUG4Mlc4KG6PM3\tcHNCVkeHUh?=
CCRF-CEMMkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17ZbGlEPTB;MUiuPFUhdk1?NFfEeGlUSU6JRWK=
NCI-H2405Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWL1ZWpEUUN3ME2xPU4yKG6PNX7NT3FLW0GQR1XS
ES7MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPFbWJpUUN3ME2xPU44PiCwTR?=NWT4OohjW0GQR1XS
BPH-1M4LsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;uU4ZKSzVyPUKwMlI5KG6PM4ixSHNCVkeHUh?=
SASNWrZV|JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlSxTWM2OD1{MD61JI5OM{S3XnNCVkeHUh?=
HuCCT1NVXreW5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\lflJKSzVyPUKwMlU5KG6PNFLkeXZUSU6JRWK=
LOUCYMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTJyLk[2JI5OMnPtV2FPT0WU
NCI-H292M3S0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLGTWM2OD1{MD63PUBvVQ>?NVrIdlhEW0GQR1XS
G-361MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXwNFlEUUN3ME2yNU4xPyCwTR?=NXjkTHA3W0GQR1XS
M059JMnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTJzLkC4JI5OM1vZcXNCVkeHUh?=
NCI-H1651M{jy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;kTWM2OD1{MT6xNUBvVQ>?NFnNU2FUSU6JRWK=
KALS-1NFTXfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\VO2lEPTB;MkGuN|khdk1?NHXLNVdUSU6JRWK=
DJM-1NYfqSGZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJzLkW5JI5ONXG3fXR5W0GQR1XS
AU565M4PYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrZZ4tKSzVyPUKxMlg{KG6PMV3TRW5ITVJ?
HCC38MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XGb2lEPTB;MkGuPVUhdk1?MXPTRW5ITVJ?
U251M3u5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVmzVJhqUUN3ME2yNk4zPyCwTR?=MnO2V2FPT0WU
ABC-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTldpZKSzVyPUKyMlY2KG6PMYrTRW5ITVJ?
SK-NEP-1NIW3elZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnVO2U{UUN3ME2yNk46OyCwTR?=MX\TRW5ITVJ?
CESSM1rVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTJ|LkG5JI5ONETQWo5USU6JRWK=
MIA-PaCa-2M3;CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDrWYVbUUN3ME2yN{4{PiCwTR?=NXzMeo9SW0GQR1XS
SUP-T1M1PQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fKPGlEPTB;MkOuOFchdk1?MoSzV2FPT0WU
L-428NXHrcHp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTJ|Lk[yJI5ONV3lb3F3W0GQR1XS
SW954MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHRRYNKSzVyPUKzMlY5KG6PMmHCV2FPT0WU
HO-1-N-1M3r6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPBT|lKSzVyPUKzMlc4KG6PNGTRSoVUSU6JRWK=
CHP-126Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPkXW92UUN3ME2yOE4yPCCwTR?=NVzDNohFW0GQR1XS
HMV-IIM{TiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLDTWM2OD1{ND6zOEBvVQ>?MoTIV2FPT0WU
NB10MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV60WHVUUUN3ME2yOE4{PyCwTR?=MYDTRW5ITVJ?
A172NHnNUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLOTWM2OD1{ND63NUBvVQ>?M1;tO3NCVkeHUh?=
MONO-MAC-6MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nmW2lEPTB;MkSuPFQhdk1?NFTyOVlUSU6JRWK=
NCI-H1650MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPCTHpSUUN3ME2yOU41KG6PNILSdopUSU6JRWK=
NH-12MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfiTWM2OD1{NT61JI5OMmnnV2FPT0WU
ML-2NWH5RWNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\rXmlKSzVyPUK1Mlc1KG6PNILBcnNUSU6JRWK=
MZ2-MELMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnpeo5zUUN3ME2yOk4zOiCwTR?=MVrTRW5ITVJ?
COLO-684MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTJ4LkSxJI5OMWDTRW5ITVJ?
HuP-T4NHKyNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;mbWlEPTB;MkeuN{BvVQ>?NFrsTIVUSU6JRWK=
SW837NFPvZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTJ5Lk[yJI5OM1zkdHNCVkeHUh?=
MDA-MB-231M1Gwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jifWlEPTB;MkeuO|ghdk1?M2rl[3NCVkeHUh?=
KYSE-140NIHxZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTJ5LkmxJI5ONIL0coJUSU6JRWK=
NOMO-1M4rSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnflTWM2OD1{OD62PEBvVQ>?NHX1b2JUSU6JRWK=
GP5dM3vpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDTTWM2OD1{OD63NkBvVQ>?MmHFV2FPT0WU
COR-L105M4PZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFT0cm5KSzVyPUK5MlQzKG6PNYXXTGp1W0GQR1XS
LS-411NNEHSN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXFTWM2OD1{OT64PEBvVQ>?M4\EVHNCVkeHUh?=
NYMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTNyLkG4JI5OMn3XV2FPT0WU
NCI-H2030NYnzfFFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fWbGlEPTB;M{CuOFUhdk1?M13Ib3NCVkeHUh?=
CCF-STTG1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nBRWlEPTB;M{GuOFIhdk1?MWXTRW5ITVJ?
NCI-H1703MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTNzLke4JI5ONU\aVoFoW0GQR1XS
TURNFLXcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33hfmlEPTB;M{KuNFMhdk1?NXHZXlhYW0GQR1XS
NOS-1NFLEfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTN{LkS0JI5OM2LWfXNCVkeHUh?=
A2058M{nNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XJNGlEPTB;M{KuPFMhdk1?NH3OPJpUSU6JRWK=
LCLC-103HNH:4fmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\rTWM2OD1|Mz6yOUBvVQ>?NHi1VG1USU6JRWK=
NCI-H510ANFPnflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXaTWM2OD1|Mz6yO{BvVQ>?MmHXV2FPT0WU
BC-1NULtVGVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTTdYJlUUN3ME2zN{44PyCwTR?=M4TibnNCVkeHUh?=
SK-CO-1NGWzNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\vTWM2OD1|ND6wNUBvVQ>?NUWzdZlnW0GQR1XS
A673MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;SWWJoUUN3ME2zOE4yPyCwTR?=NGrCd2FUSU6JRWK=
VM-CUB-1NX[1fW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1G5eGlEPTB;M{SuOlkhdk1?NFGzW2ZUSU6JRWK=
HHMnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTN3LkC2JI5ONIPPcpFUSU6JRWK=
CAL-27M1PCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTN3LkG2JI5OMlvhV2FPT0WU
NEC8MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHhWYFKSzVyPUO1MlM4KG6PNUTkO5g{W0GQR1XS
BxPC-3NHnnUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPHTWM2OD1|Nj65NUBvVQ>?MofSV2FPT0WU
SNB75NVnVdG95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLCdnhKSzVyPUO3MlI1KG6PMX3TRW5ITVJ?
NB13MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4OwN2lEPTB;M{iuNlMhdk1?MWfTRW5ITVJ?
SK-OV-3MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnm3TWM2OD1|OD63OEBvVQ>?M4ixUHNCVkeHUh?=
ME-180NELrRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTN6Lkigcm0>NHPMRnlUSU6JRWK=
JiyoyeP-2003NF\hXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnKN5dJUUN3ME2zPU4{QCCwTR?=MYnTRW5ITVJ?
LU-134-AMly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1j6VWlEPTB;NECuNFIhdk1?MkPkV2FPT0WU
LS-123MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTRyLkK4JI5ONW[yepNJW0GQR1XS
COLO-800MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\oeWlEPTB;NECuOVYhdk1?MXXTRW5ITVJ?
LB831-BLCMl;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jZcWlEPTB;NEGuPFUhdk1?MmS0V2FPT0WU
NCI-H747NVSwd4hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlT2TWM2OD12Mj6yPEBvVQ>?M4jh[3NCVkeHUh?=
MZ7-melMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;sUmlEPTB;NEKuOlYhdk1?Ml3OV2FPT0WU
GT3TKBNUj0VVVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnGOnNKSzVyPUSyMlczKG6PMVXTRW5ITVJ?
MOLT-16NEi5b|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjXTWM2OD12Mz6wOUBvVQ>?M3TZb3NCVkeHUh?=
23132-87M2jjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33HZmlEPTB;NEOuNFUhdk1?MWjTRW5ITVJ?
PF-382MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nBbmlEPTB;NESuNlIhdk1?M1Tve3NCVkeHUh?=
ES3NIPWcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;LTWM2OD12ND62JI5OM2XUWXNCVkeHUh?=
SW756MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTR3LkG0JI5ONFHEVIRUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hertel LW, et al. Cancer Res, 1990, 50(14), 4417-4422.

[2] Bruns CJ, et al. Clin Cancer Res, 2000, 6(5), 1936-1948.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02567409 Not yet recruiting Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Stage IV Bladder Urothelial Carcinoma National Cancer Institute (NCI) August 2016 Phase 2
NCT02627443 Not yet recruiting High Grade Ovarian Serous Adenocarcinoma|Ovarian Endometrioid Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primar  ...more High Grade Ovarian Serous Adenocarcinoma|Ovarian Endometrioid Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer National Cancer Institute (NCI) August 2016 Phase 2
NCT02595892 Not yet recruiting Ovarian Serous Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma National Cancer Institute (NCI) July 2016 Phase 2
NCT01676259 Not yet recruiting Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer Silenseed Ltd June 2016 Phase 2
NCT02336087 Not yet recruiting Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer City of Hope Medical Center|National Cancer Institute (NCI) June 2016 Phase 1

view more

Chemical Information

Download Gemcitabine SDF
Molecular Weight (MW) 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LY-188011, NSC 613327
Solubility (25°C) * In vitro DMSO 15 mg/mL (56.99 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2'-​deoxy-​2',​2'-​difluoro-cytidine

Customer Product Validation (3)


Click to enlarge
Rating
Source Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck
Method Xenograft Study
Cell Lines Athymic nude mice
Concentrations 120 mg/kg
Incubation Time 14 d
Results Gemcitabine treatment caused a threefold increase in stemness-high cell population.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck
Method Immunofluorescence
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 72 h
Results To finally investigate whether incorporation of drugs into RNA could be a general mechanism inducing SG assembly, we tested other chemotherapeutics known to incorporate into RNA, such as 5-azacytidine and 6-thioguanine, or as control, chemotherapeutics known to incorporate mainly into DNA, such as trifluorothymidine (TFT) or gemcitabine. HeLa cells treated with 5-azacytidine and 6-thioguanine displayed TIAR-positive foci, whereas HeLa cells treated with TFT or gemcitabine did exhibit such foci even with higher concentrations applied.

Click to enlarge
Rating
Source Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck
Method MTT assays
Cell Lines MCF7 cells, MCF10A cells
Concentrations 0.01-100 μM
Incubation Time 48 h
Results Gemcitabine potently inhibited the survival of MCF10A cells in a dose-dependent manner. The highest level of inhibition was observed with Gemcitabine HCl in concentration of 0.01 μM in MCF7 cells

Product Use Citation (13)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA/RNA Synthesis Products

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Recently Viewed Items

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us